These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11870441)

  • 41. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
    Grigorescu-Sido P; Drugan C; Alkhzouz C; Zimmermann A; Coldea C; Denes C; Grigorescu MD; Cret V; Bucerzan S
    Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A; Mewawalla P; Jagadeesh S; Kabra M; Phadke SR; Verma IC; Puri RD; Gupta N; Kishnani PS; Mistry PK
    Indian Pediatr; 2011 Oct; 48(10):779-84. PubMed ID: 22080680
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
    Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ; Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Rosenbloom BE; Scott CR; Wappner RS; Zimran A
    Am J Med; 2002 Aug; 113(2):112-9. PubMed ID: 12133749
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC; Chien YH; Lai MY; Hwu WL
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Type I Gaucher disease (GDI) in three siblings: enzyme replacement treatment (ERT) required.
    Gucev ZS; Tasic V; Pop-Jordanova N; Kirovski I; Stomnaroska O; Martinova M; Jancevska A; Kremensky I; Sinigerska I
    Prilozi; 2009 Jul; 30(1):233-40. PubMed ID: 19736544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gaucher disease in Iraqi children (Clinical, diagnostic & therapeutic aspects).
    Thejeal RF; Kadhum AJ
    Pak J Med Sci; 2016; 32(2):319-23. PubMed ID: 27182231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
    Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
    Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deterioration of the auditory brainstem response in children with type 3 Gaucher disease.
    Campbell PE; Harris CM; Vellodi A
    Neurology; 2004 Jul; 63(2):385-7. PubMed ID: 15277647
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ultrastructural features of gaucher disease treated with enzyme replacement therapy presenting as mesenteric mass lesions.
    Fowler DJ; Weber MA; Anderson G; Malone M; Sebire NJ; Vellodi A
    Fetal Pediatr Pathol; 2006; 25(5):241-8. PubMed ID: 17438664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
    Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
    Brunel-Guitton C; Rivard GE; Galipeau J; Alos N; Miron MC; Therrien R; Mitchell G; Lapierre G; Lambert M
    Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
    Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI; Giraldo P; Giralt M
    Sangre (Barc); 1997 Jun; 42(3):189-94. PubMed ID: 9381260
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term treatment outcomes in Gaucher disease.
    Charrow J; Scott CR
    Am J Hematol; 2015 Jul; 90 Suppl 1():S19-24. PubMed ID: 26096742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Population-based cohort of 500 patients with Gaucher disease in Israel.
    Jaffe DH; Flaks-Manov N; Benis A; Gabay H; DiBonaventura M; Rosenbaum H; Joseph A; Bachrach A; Leventer-Roberts M
    BMJ Open; 2019 Jan; 9(1):e024251. PubMed ID: 30670517
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thrombocytosis associated with enzyme replacement therapy in Gaucher disease.
    Dweck A; Blickstein D; Elstein D; Zimran A
    Acta Haematol; 2002; 108(2):94-6. PubMed ID: 12187028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.